WAVEMAN · COMPANY

RGNX · Regenxbio Inc.

LIVE

TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475

← ALL COMPANIES

RGNX

Name: REGENXBIO Inc. (RGNX) insider trading and ownership data
Creator: WaveMan
License: https://wave-man.com/terms

REGENXBIO Inc.

PHARMA & BIOTECH · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · CIK 0001590877

FORM 144 · 1☆ WATCH

INSIDER NET · 180D

$9.4K

open-market buys minus sells, Form 4 codes P and S

INSIDER BUYERS · 180D

CONGRESS BUYERS · 1Y

FUNDS ADDED · QTR

13F, latest reported quarter

REVENUE GROWTH

+104.5%

XBRL, annual

NET MARGIN

-113.8%

CONVERSIONS · 180D

codes C/M, not in net · $305.6K priced

SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST

INSIDERS

net +$9.4K over 180 days

+$231.1K over 90 days

more than 68% of Pharma & Biotech

CONGRESS

no member of Congress has reported trading it

FUNDS

86 funds added or opened last quarter

more than 60% of Pharma & Biotech

REVENUE

+104.5% year over year

more than 85% of Pharma & Biotech

MARGIN

-113.8% net margin

below 67% of Pharma & Biotech

BUYBACKS

no share repurchases reported

SHORT

no short interest reported

THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET

86 funds added or opened positions in the latest 13F quarter, of 166 holders.

The year, with the filings on it

Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail

TOTAL 12M RETURN -2.0%

-2.0%12M

INSIDER BUYINSIDER SELLFORM 144

INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY

Live price

Daily candles from TradingView, on their licence — no filings are marked on this one

WHY THIS NAME IS ON THE DESK

Insiders are net buyers of their own stock.

The record shows a net $9.4K bought by insiders over 180 days, 86 funds added last quarter, $517.6K in planned Form 144 sales. Every figure is a federal filing, dated the day it became public.

Backtest this pattern Open the screener

Same sector, ranked by filing activity

Sector from the SEC's own SIC classification

UTHR CPIX MRNA REGN LLY ALNY ELF CITR MDGL DNA VRTX NUVL

Insider transactions

Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, REGENXBIO Inc. insiders bought a net $9.4K of stock across 50 Form 4 purchases and sales, with 1 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-06.

INSIDER

FILED

VALUE

Ciongoli Gregory Austin

Director

BUY

2026-08-27

53,407.0

$499.7K

Ciongoli Gregory Austin

Director

BUY

2026-08-26

49,196.0

$449.7K

PAKOLA STEVE

Chief Medical Officer

SELL

2026-07-02

2,161.0

$29.5K

PAKOLA STEVE

Chief Medical Officer

SELL

2026-07-01

36,725.0

$472.3K

PAKOLA STEVE

Chief Medical Officer

SELL

2026-06-29

19,608.0

$216.5K

50 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 45 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders

13F · holdings as of the latest quarter funds have reported

BlackRock, Inc.

6,397,440.0 sh

$76.6M

Redmile Group, LLC

4,368,804.0 sh

$52.3M

STATE STREET CORP

2,971,173.0 sh

$35.6M

JPMORGAN CHASE & CO

2,214,169.0 sh

$26.2M

VANGUARD CAPITAL MANAGEMENT LLC

2,107,557.0 sh

$25.2M

SCHEDULE 13D/G

No 5%+ ownership filings

Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.

Planned sales · Form 144

Filed before the sale — intent, not a trade

Stephen J. Pakola

FILED 2026-07-01

$517.6K

Fund concentration

N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show

JPMorgan Small Cap Growth Fund

$11.1M POSITION · AS OF 2026-03-31

0.5%

Virtus Biotech Clinical Trials Etf

$178.5K POSITION · AS OF 2026-04-30

0.5%

VANGUARD MARKET NEUTRAL FUND

$2.0M POSITION · AS OF 2026-03-31

0.5%

Global X Genomics & Biotechnology ETF

$185.2K POSITION · AS OF 2026-02-28

0.4%

ALPS Medical Breakthroughs ETF

$407.9K POSITION · AS OF 2026-02-28

0.3%

Harbor Human Capital Factor US Small Cap ETF

$437.6K POSITION · AS OF 2026-04-30

0.3%

SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK

Clinical pipeline

ClinicalTrials.gov · 13 registered trials, 7 still enrolling or running — a status change here is dated weeks before the press release

Phase 3

1 ACTIVE

Not applicable

4 ACTIVE

Multi-phase

2 ACTIVE

TRIALS MATCHED TO THIS TICKER BY SPONSOR NAME · STUDIES RUN UNDER A SUBSIDIARY'S OWN NAME ARE NOT INCLUDED

Fundamentals

Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all

	2025-12	2024-12	2023-12	2022-12
REVENUE	$170.4M	$83.3M	$90.2M	$112.7M
OPERATING INCOME	$-161.2M	$-233.3M	$-268.1M	$-262.9M
NET INCOME	$-193.9M	$-227.1M	$-263.5M	$-280.3M
EPS (DILUTED)	-3.76	-4.59	-6.02	-6.50
OPERATING CASH FLOW	$-124.0M	$-173.1M	$-218.4M	$-207.5M
CASH	$34.5M	$57.5M	$34.5M	$97.0M

SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-06 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE